Search Results
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
their roles in pioneering CAR T-cell therapy. Sadelain talked about the early stages of the development of CAR molecules and the selection of the protein CD19 as a therapeutic target in CAR T-cell therapy. Levine detailed the process of turning CAR T-cell therapy from a technology developed in academic labs
More news about: Broad Institute
Oct 31, 2025, 12:32 ET InsCorp, Inc. Reports EPS Growth of 23% Y/Y in 3Q25
growth in interest-bearing transaction balances of 31% and non-interest bearing deposit growth of 14% over the past year. Total CD balances grew 10% Y/Y in 3Q25 and decreased to 58% of deposits compared to 60% a quarter vs. 61% a year ago. Non-interest bearing and interest-bearing
More news about: INSBANK
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
(upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). The updated indication statement allows the use of Rinvoq prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of
More news about: AbbVie
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 30, 2025, 16:44 ET PEOPLES FINANCIAL SERVICES CORP. Reports Unaudited Third Quarter and Year to Date 2025 Earnings
30, 2025, and December 31, 2024, respectively. As part of strategic balance sheet management initiatives, the Company reduced its higher rate brokered CD portfolio by $94.2 million during the first nine months of 2025. The Company's deposit base is diversified and consisted of
More news about: Peoples Financial Services Corp.
Oct 30, 2025, 11:15 ET The VerifiedX Foundation Unveils "Butterfly" The World's First Self-Custodial Social P2P Payment and Commerce Platform for Everyday Users
https://discord.gg/7cd5ebDQCjTwitter (X):
More news about: VerifiedX.io
Oct 30, 2025, 11:15 ET The VerifiedX Foundation Unveils "Butterfly" The World's First Self-Custodial Social P2P Payment and Commerce Platform for Everyday Users
https://discord.gg/7cd5ebDQCjTwitter (X):
More news about: VerifiedX.io
Oct 30, 2025, 10:13 ET Federal Reserve Action Causes Decline in CD Rates, Finds CD Valet Data
tool to entice that behavior among savers." CD Valet offers the most comprehensive source of CD rates available today, with over 38,500 CD rates tracked from nearly 5,000 financial institutions. Over the past month, CD Valet found that 4,264 rates have decreased with an average reduction
More news about: CD Valet
Oct 30, 2025, 08:36 ET Blondie's No Exit Deluxe Reissue -- Remastered, Expanded, and Available for the First Time on Vinyl -- Out This Friday via BMG
Out Friday via BMG and available in digital, 2CD, crystal glass clear 2LP, and black 2LP vinyl pressings, the definitive new edition celebrates one of Blondie's most pivotal chapters — the moment
More news about: Blondie
Oct 30, 2025, 08:34 ET Inflectra Launches Rapise 8.6 with Inflectra.ai: Ushering in a New Era of Secure, Embedded Generative AI for Test Automation
Additionally, a new command-line switch generates test results in the industry standard JUnit XML format for seamless integration with modern CI/CD pipelines. Rapise 8.6 is a demonstration of Inflectra's commitment to delivering world-class, cutting-edge,
More news about: Inflectra Corporation
Oct 30, 2025, 08:00 ET Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting
Preclinical findings highlight PLT012's first-in-class anti-CD36 mechanism of action that reprograms immune-metabolic pathways to suppress Tregs, enhance CD8 ⁺ T-cell responses, and induce durable tumor control; and
More news about: Pilatus Biosciences
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia a aprovação e o lançamento do MINJUVI® (tafasitamabe) na Argentina
que não são elegíveis para transplante4. "O Minjuvi® tem um mecanismo de ação único e inovador que tem como alvo o CD19 e representa um avanço significativo no tratamento de LDGCB. É uma imunoterapia direcionada que oferece remissão sustentada para pacientes adultos
More news about: Knight Therapeutics Inc.
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia la aprobación y el lanzamiento de MINJUVI® (tafasitamab) en Argentina
DLBCL que no son elegibles para el trasplante4. "MINJUVI® tiene un mecanismo de acción único e innovador dirigido a CD19 y representa un avance significativo en el tratamiento del LDLBG. Es una inmunoterapia dirigida que ofrece una remisión sostenida para pacientes adultos
More news about: Knight Therapeutics Inc.
Oct 30, 2025, 07:30 ET Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
received drug volumes above 40% of their tumor burden. In addition, in thirteen of fourteen matched pair biopsy slides, a notable increase in activated CD4+ and CD8+ T cells was observed in the tumor microenvironment in response to INT230-6 treatment. Representative images can be found in the paper," said Anthony El-Khoueiry
More news about: Intensity Therapeutics Inc.
Oct 30, 2025, 04:30 ET Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria
ALY-301 is a first-in-class cis-targeting bispecific antibody designed to selectively deplete mast cells by binding both c-Kit and CD203c. This differentiated profile of ALY-301 is expected to enable chronic dosing in mast cell dependent diseases such as Chronic Urticaria, while avoiding
More news about: Alys Pharmaceuticals
Oct 30, 2025, 04:00 ET AbolerIS Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer
autoimmune and inflammatory diseases. The Company is advancing potentially best-in-class and first-in-class immunomodulatory antibodies that target CD45RC, a key regulator of the immune system. AbolerIS' lead program, ABO21009, is designed to demonstrate broad efficacy in multiple autoimmune and inflammatory
More news about: AbolerIS Pharma
Oct 29, 2025, 18:34 ET CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
associated with traditional CRISPR/Cas9 methods. In the presented study, CREATE Medicines used RetroT to successfully insert a CD19-CAR transgene into human T cells. RetroT uses the LINE-1 retrotransposon, the only active "jumping gene" in the human genome, to integrate
More news about: CREATE Medicines, Inc.
Oct 29, 2025, 14:58 ET Sepsis Diagnostics Market to Reach USD 1,790.9 million by 2032, Growing At An 7.85% CAGR - Credence Research
response. Procalcitonin (PCT) and C-reactive protein (CRP) are well-established biomarkers, and new markers like presepsin and the pan-leukocyte marker CD64 are gaining traction. These tools provide clinicians with a more nuanced picture of the patient's condition, helping to differentiate sepsis from non-infectious
More news about: Credence Research Inc.
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
healthcare provider does not recommend TNF blockers. Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection
More news about: AbbVie
Oct 29, 2025, 07:00 ET BANKFIRST CAPITAL CORPORATION Reports Third Quarter 2025 Earnings of $5.20 Million
Alabama. BankFirst offers a wide variety of services for businesses and consumers. The Bank also offers internet banking, no-fee ATM access, checking, CD, and money market accounts, merchant services, mortgage loans, remote deposit capture, and more. For more information, visit
More news about: BankFirst Capital Corporation
Oct 29, 2025, 06:04 ET Global Leaders Explore How Quality Is Becoming a Strategic Advantage
https://events.teams.microsoft.com/event/558e8f95-7eb8-4297-9c58-671057602a6e@8408cd55-d19b-48ea-9fbf-af82307fe251 Seats are limited. Join global leaders this World Quality Month to explore
More news about: Shainin
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Miltenyi Biomedicine's Zamtocabtagene autoleucel is a CAR-T cell therapy designed to simultaneously target both CD19 and CD20 proteins expressed on B cells. This innovative investigational therapy has been granted inclusion in the European Union's Priority Medicines
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 17:18 ET Pacific West Bancorp ("PWBK") Announces Third Quarter Financial Results
Investments - CD
More news about: Pacific West Bancorp
Oct 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Oct 28, 2025, 08:00 ET CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors
Proof-of-mechanism: Paired biopsies confirmed CAR+ immune cells infiltrating tumors, with immune remodeling and CD8 T-cell recruitment. Safety data and repeat dosing: Over 200 monotherapy doses administered with
More news about: CREATE Medicines, Inc.